Bridge­Bio spot­lights 12 and 18-month da­ta for po­ten­tial achon­dropla­sia drug in chil­dren

Bridge­Bio tout­ed longer-term da­ta for its achon­dropla­sia drug in­fi­gra­tinib from a mid-stage tri­al on Tues­day, set­ting the treat­ment up to be a fu­ture com­peti­tor for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.